Sotsiaalmeedia

Screenings during pregnancy

During pregnancy, at least two ultrasounds are performed on all women:

  • Measuring nuchal translucency during the 11th to 13th week of pregnancy
  • The analysis of the baby’s anatomy during the 20th to 21st week of pregnancy.
  • These analyses are free of charge. In case of medical indications, additional ultrasounds will be performed. In addition, we offer optional ultrasound analyses for a fee.

Screenings during the 1st trimester

OSCAR-test – ultrasound + blood serum test

During the 11th to 13th + 6 weeks of pregnancy, there will be an ultrasound analysis. During this, the back of the head of the foetus or the so-called nuchal translucency will be observed. In addition, we check for the presence of the nose bone, heartbeat rate, flow of blood on the tricuspid valve and ductus venosus. If the foetus has increased nuchal translucency, there is an increased chance of chromosome disorders and additional testing is required. Normal results stay below 3.0 mm.

A blood test is taken on the 10th week of pregnancy. We take the content of two markers (fb-hCG+papp-a). The results will be entered into a special computer program ViewPoint along with additional information like your ethnic background, the number of previous births, extent of pregnancy, weight, height, other risk factors and concurrent diseases.

  • Please refer to room RB0116 in the ground floor at the pre-delivery department 15 minutes before your analysis.
  • Ultrasound rooms are located at the Ravi 18 B-corpus of the maternity hospital. Additional information from the women’s clinic reception or a midwife.
  • You can provide your blood sample at the East Tallinn Central Hospital clinic, on the 1st floor of the C-corpus of Ravi 18, room RC0247.

Screenings during the 2nd trimester

Analysis of the foetal anatomy

We use 3D and 4D ultrasound technologies for this analysis. We check whether the child has visible deviations in their internal organs or limbs, whether there is enough amniotic fluid and where the placenta is located. Using the measurements of the foetus, we can determine the duration of the pregnancy and the delivery date with the accuracy of 1.5-2 weeks. Identification of the baby’s gender depends on its position.

  • Ultrasound rooms are located in the maternity hospital, Ravi 18 B-corpus basement and ground floors. Additional information from the reception of the women’s clinic or from a midwife.

Paid analyses

Optional ultrasound: picture or video of the foetus on a 3D-device.

  • This ultrasound will be carried out upon the patient’s wish, without any medical indications.
  • The best time for this analysis is between the 24th and 32nd week because then there is enough amniotic fluid surrounding the foetus and it is no longer in the pelvis.
  • It may be that the imaging process is more difficult or even impossible due to the position of the baby or the placenta.
  • The analysis costs 66 euros.

To register for an appointment for paid analysis and for additional information about opening hours and prices call 666 1900.

  • Ultrasound rooms are located at the maternity hospital at Ravi 18 B-corpus. Additional information from the reception at the women’s clinic or a midwife.

soelu2

NIPTIFY screening  test

The NIPTIFY screening test analyzes the five most common fetal chromosomal disorders and determines the sex of the fetus:

  • Down syndrome (trisomy 21)
  • DiGeorge syndrome (22q11 microdeletion)
  • Edwards syndrome (trisomy 18)
  • Patau syndrome (trisomy 13)
  • Turner syndrome (monosomy X)

Additionally, a comprehensive study of the whole genome of the fetus is carried out, which can identify important abnormalities affecting the fetus’s health or the mother. They are reported under the name INCIDENTAL FINDINGS. An incidental finding can be a copy number change of an entire chromosome or microdeletion. Seven microdeletions are considered to be clinically significant, which the study can also identify:

  • Williams-Beuren syndrome (7q11)
  • 1p36 deletion syndrome
  • Angelman and Prader-Willi syndrome (15q)
  • Wolf-Hirschhorn syndrome (4p)
  • Jacobsen syndrome (11q)
  • Cri-du-chat syndrome (5p)
  • Langer-Giedion syndrome (8q).

The NIPTIFY test is available from 10+ weeks of pregnancy until the end of the pregnancy. The test is for a singleton pregnancy. The test is also available in case of in vitro fertilization and using the donor egg(s). It is necessary to confirm the heartbeat of the fetus with an ultrasound. The mother’s blood sample is required for the analysis. The patient can eat and drink before the procedure. The exclusion criteria of the NIPTIFY test are multiple pregnancies or malignant tumors during pregnancy.

Read more NIPTIFY.ee

NIPTIFY screening test price – 300 euros

PrenatalSafe screening for twins for a fee

PrenatalSafe screening can be done starting from 10+ weeks of pregnancy until the end of pregnancy.  The screening is suitable for people expecting twins. The test gives results also in case of in vitro fertilisation and in case of using a donor egg/embryo. The chorionicity of the heartbeat and placenta have to be confirmed by ultrasound. For the screening, a simple blood sample is taken from the mother. Before giving the sample, she can eat and drink as usual.  The screening CANNOT be done if the pregnant woman has chromosome anomalies, or a malignant tumour has been diagnosed during pregnancy. In case of a vanishing twin, the latter may influence the result and quality of the screening.

  • THE MAIN PANEL. PrenatalSafe® 3 assesses the risk of foetal trisomies, like those of chromosomes 13 (Patau Syndrome), 18 (Edwards Syndrome), and 21 (Down Syndrome), and includes the determination of Y-chromosome in the sample, giving a hint to the fetal sex.
  • EXTENDED PANEL FOR MONOCHORIONIC (one placenta) PrenatalSafe®Plus assesses the risks of foetal trisomies, like those of chromosomes 9, 16, 13 (Patau Syndrome), 18 (Edwards Syndrome), and 21 (Down Syndrome), the risk of sex chromosomes anomalies XO (Turner Syndrome), XXY (Klinefelter Syndrome), XYY (Jacobs Syndrome), XXX (Trisomy X) and the risk caused by 9 microdeletions (DiGeorge, Cri-du-chat, Prader-Willi, Angelman, 1p36 del, Wolf-Hirschhorn, Jacobsen, Langer-Giedion, Smith-Magenis). In addition, it includes the determination of Y-chromosome in the sample, giving a hint to the foetal sex.
  • EXTENDED PANEL FOR DICHORIONIC (two placentas) TWINS. PrenatalSafe® Karyo test assesses the risk of trisomy for chromosomes 13 (Patau Syndrome), 18 (Edwards Syndrome), and 21 (Down Syndrome), and all other autosomal chromosomes. The screening analyses the whole genome of the foetus. In addition, it includes the determination of Y-chromosome in the sample, giving a hint to the foetal sex.

The cost of the PrenatalSafe screening test for twins is 416 euros. The Illumina VeriSeq (the laboratory located in Italy) test PrenatalSAFE is mediated to East Tallinn Central Hospital by a biotehnology company Tervisetehnoloogiate Arenduskeskus AS  (Competence Centre on Health Technologies, CCHT).

Additional information regarding NIPTIFY screening test and making an appointment at Oscar@itk.ee or telephone 5301 9421.

Close modal
Go to top